CONNECTA Therapeutics

CONNECTA Therapeutics news and milestones

CONNECTA Therapeutics: 7 headlines on record, 1 headline in the last 90 days.

Data updated Nov 17, 2026 · Back to the company report
7Headlines
1In 90 days
0Milestones

Headlines

Sep 102026
Blog
€3.1 million financing led by new investor Clave Capital, with participation from existing investors Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Frag…
Jul 22026
Blog
Preclinical data highlight restoration of cognitive, behavioral and synaptic deficits in Fragile X syndrome models Barcelona, Spain - 2 July 2026 - CONNECTA Therapeutics, a clini…
Jun 102026
Blog
Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a…
Sep 9, 20252025
Blog
CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepa…
Mar 4, 20252025
Blog
CONNECTA Therapeutics has announced positive results from its Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics profile of its drug candidate CTH12…
Feb 18, 20252025
Blog
The European Innovation Council (EIC) announced yesterday that CONNECTA Therapeutics has been selected for grant and equity funding, following the last EIC Accelerator cut-off. C…
Feb 12, 20242024
Blog
The Phase IIa study will assess the efficacy of CTH120 as an innovative therapy in adults with FXS, the most common form of inherited intellectual disability without a specific t…
Sources: the outlets named on each headline, each story once

How to cite

CONNECTA Therapeutics, News. Alion, Nov 17, 2026. https://alion.io/company/connectatherapeutics/news

.json · .md · CC BY-SA 4.0